Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer

A useful candidate for small-cell lung cancer (SCLC) therapy is immune checkpoint blockade therapy targeting programmed death-1 (PD-1) and its ligand, PD-L1. Furthermore, rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate, and enhancer of zeste homologue...

Full description

Saved in:
Bibliographic Details
Published in:Mol Clin Oncol
Main Authors: Saito, Motonobu, Saito, Katsuharu, Shiraishi, Kouya, Maeda, Daichi, Suzuki, Hiroyuki, Minamiya, Yoshihiro, Kono, Koji, Kohno, Takashi, Goto, Akiteru
Format: Artigo
Language:Inglês
Published: D.A. Spandidos 2018
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5776411/
https://ncbi.nlm.nih.gov/pubmed/29435295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1536
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items